Neoolife

Neoolife is a pre-clinical stage Bio-MedTech start-up based in Pittsburgh, Pennsylvania, with a presence in Europe, including Germany, Italy, and Spain. The company specializes in developing tissue-engineered biomimetic cardiovascular products, focusing on biomimetic heart valves and cardiovascular patches. These products are designed to promote endogenous tissue regeneration and are suitable for both minimally invasive and surgical applications, particularly in treating heart valve diseases like tricuspid valve regurgitation. The multidisciplinary team at Neoolife brings over 130 years of combined experience in biomedical technology and device therapy. Their core technology features durable, non-thrombogenic, and calcification-resistant polymeric products. Neoolife is also pioneering a platform technology called Double Component Deposition (DCD), licensed from the University of Pittsburgh and RiMED, aimed at enhancing heart valve replacement solutions. The company is positioned to address a significant market for transcatheter valve implantation, estimated at around $10 billion annually, as it advances its product development and prepares for future growth opportunities.

• Employees 13
• Founded 2020